Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Mar 2020

Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N, Le Tourneau C, Sablin M-P, Lacroix L, Enrico D, Miran I, Jovelet C, Bièche I, Soria J-C, Bertucci F, Bonnefoi H, Campone M, Dalenc F, Bachelot T, Jacquet A, Jimenez M, André F

Abstract excerpt

BACKGROUND: α-Selective phosphatidylinositol 3-kinase (PI3K) inhibitors improve outcome in patients with PIK3CA-mutated, hormone receptor-positive (HR+)/Her2- metastatic breast cancer (mBC). Nevertheless, it is still unclear how to integrate this new drug family in the treatment landscape. PATIENTS AND METHODS: A total of 649 patients with mBC from the SAFIR02 trial (NCT02299999), with available mutational...

Topics

Join the communities discussing this publication.

Biomarkers, Tumor
Breast Neoplasms
Class I Phosphatidylinositol 3-Kinases
Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Phosphatidylinositol 3-Kinases

Receptor, ErbB-2

Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 32067679
DOI: 10.1016/j.annonc.2019.11.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.PMID 32067679Read ↗

PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients.Semantic proximity Read ↗

PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials.Semantic proximity Read ↗

PIK3CA Mutational Profiling in a Patient Cohort with HR+/HER2- Advanced Metastatic Breast Cancer at a Tertiary Cancer CenterSemantic proximity Read ↗

A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.Semantic proximity Read ↗

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy.Semantic proximity Read ↗

Frequency and spectrum of PIK3CA somatic mutations in breast cancer.Semantic proximity Read ↗

PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer PatientsSemantic proximity Read ↗

Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.Semantic proximity Read ↗

Analysis of PIK3CA Mutations with Clinicopathological Features and Prognosis in Breast cancer patients with Undergoing Neoadjuvant TherapySemantic proximity Read ↗

Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers.Semantic proximity Read ↗

PIK3CA gene mutations in the helical domain correlate with high tumor mutation burden and poor prognosis in metastatic breast carcinomas with late-line therapies.Semantic proximity Read ↗

Survival analysis of patients with early breast cancer associated with PIK3CA mutationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.